Recombinant Full Length Human E2F1, Flag-tagged

• Cat.No.: E2F1-9882HFL
• Product Overview: Recombinant Full Length Human E2F1, fused with C-terminal Flag tag, was expressed in mamanlian cells.

Specification

• Source: Mamanlian cells
• Species: Human
• Tag: Flag
• Form: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol.
• Molecular Mass: 46.7 kDa
• Purity: >80% as determined by SDS-PAGE and Coomassie blue staining
• Concentration: >50 ug/mL as determined by microplate BCA method
• Shipping: The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.

Gene Information

• Gene Name: E2F1 E2F transcription factor 1 [ Homo sapiens ]
• Official Symbol: E2F1
• Synonyms: RBP3; E2F-1; RBAP1; RBBP3; transcription factor E2F1; PBR3; PRB-binding protein E2F-1; RBAP-1; RBBP-3; retinoblastoma-associated protein 1; retinoblastoma-binding protein 3
• Gene ID: 1869
• mRNA Refseq: NM_005225
• Protein Refseq: NP_005216
• MIM: 189971
• UniProt ID: Q01094

Reviews

06/20/2022

The versatility of the E2F1 protein is truly remarkable, as it can be employed across a wide range of applications in my research.

01/16/2022

In addition to its outstanding quality, the manufacturer of the E2F1 protein offers excellent technical support that can effectively address any challenges I may encounter.

03/23/2016

Their dedicated team of experts is readily available to provide guidance and assistance, ensuring a seamless integration of the E2F1 protein into my experimental setup.

Q&As

Can E2F1 be used in prognostic assessments for cancer patients?

E2F1 expression patterns may serve as prognostic indicators, helping predict the likelihood of disease progression and informing treatment strategies.

How does E2F1 contribute to drug resistance in cancer?

E2F1 overexpression has been linked to drug resistance in cancer cells, presenting a challenge in chemotherapy and necessitating further research for effective solutions.

What other diseases or conditions are associated with E2F1 dysfunction?

E2F1 dysregulation has been implicated in various diseases beyond cancer, including neurodegenerative disorders and cardiovascular diseases.

Are there any clinical trials targeting E2F1 for therapeutic interventions?

Clinical trials are investigating the potential of targeting E2F1 in cancer treatment, exploring novel drugs and treatment approaches.

How does E2F1 interact with other proteins in cellular processes?

E2F1 interacts with several proteins to form complexes that regulate gene expression, influencing cellular processes such as DNA replication and repair.